PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
July 23, Chicago – PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma…
PolyActiva commences its first Phase I clinical trial
PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is safe and well tolerated…